A 75-year-old Man with Prostate Cancer

Expert oncologist Alicia Morgans, MD, MPH, shares details on the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.

Following her review of a patient case of metastatic castration-resistant prostate cancer, Alicia Morgans, MD, MPH, highlights the range of treatment options in this setting.

Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.

Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.

Key opinion leader Alicia Morgans, MD, MPH, considers the role of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management.

Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.

Expert oncologist Alicia Morgans, MD, MPH, shares her hope for future improvements in metastatic castration-resistant prostate cancer management as the landscape continues to evolve.